Lisuride (BioDeep_00000026846)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


3,3-diethyl-1-[(4S,7R)-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaen-4-yl]urea

化学式: C20H26N4O (338.2106506)
中文名称: 利修来得
谱图信息: 最多检出来源 Homo sapiens(urine) 27.27%

分子结构信息

SMILES: CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C
InChI: InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1

描述信息

Lisuride is only found in individuals that have used or taken this drug. It is used for the management of Parkinsons Disease.Lisuride is an anti-Parkinson drug chemically related to the dopaminergic ergoline Parkinsons drugs. Lisuride binds to the 5-HT(1A) and 5-HT(2A/2C) receptors. It is also thought to bind to the dopamine receptor and to act as a dopamine agonist. Evidence has also emerged that Lisuride also binds to the Histamine H1 receptor. Lisuride is also used to lower prolactin and, in low doses, to prevent migraine attacks.
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CA - Ergot alkaloids
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

同义名列表

34 个代谢物同义名

3,3-diethyl-1-[(4S,7R)-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaen-4-yl]urea; N-((8alpha)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea; N-((8a)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea; N-((8α)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea; Schering brand 2 OF lisuride maleate; Schering brand 1 OF lisuride maleate; Lisuride maleate, (8beta)-isomer; IPRAD brand OF lisuride maleate; Roche brand OF lisuride maleate; Lisuride, (8alpha)-(+-)-isomer; Hydrogen maleate, lysuride; Lysuride hydrogen maleate; Lisuride phosphate (1:1); Hydrochloride, lisuride; Carbamide, methylergol; Lisuride hydrochloride; Lisuride maleate (1:1); Methylergol carbamide; Mesylate, lisuride; Lisuride mesylate; Maleate, lisuride; Lisuride Maleate; SCHEMBL14507250; s-(-)-lisuride; Lisuridum; Dopergine; Lisurida; Dopergin; Lisuride; Lysurid; Revanil; Lysenyl; Cuvalit; Arolac



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Annika Gocht, Jörg H W Distler, Bernd Spriewald, Martina Ramsperger-Gleixner, Michael Weyand, Stephan M Ensminger, Christian Heim. Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts. Transplant immunology. 2018 08; 49(?):43-53. doi: 10.1016/j.trim.2018.04.002. [PMID: 29649585]
  • Uwe Oberländer, Katrien Pletinckx, Anja Döhler, Nora Müller, Manfred B Lutz, Thomas Arzberger, Peter Riederer, Manfred Gerlach, Eleni Koutsilieri, Carsten Scheller. Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC neuroscience. 2011 Nov; 12(?):116. doi: 10.1186/1471-2202-12-116. [PMID: 22085464]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Robert A Ettlin, Junji Kuroda, Stephanie Plassmann, Makoto Hayashi, David E Prentice. Successful drug development despite adverse preclinical findings part 2: examples. Journal of toxicologic pathology. 2010 Dec; 23(4):213-34. doi: 10.1293/tox.23.213. [PMID: 22272032]
  • Melanie Königshoff, Rio Dumitrascu, Sergey Udalov, Oana Veronica Amarie, Rudolf Reiter, Friedrich Grimminger, Werner Seeger, Ralph Theo Schermuly, Oliver Eickelberg. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax. 2010 Nov; 65(11):949-55. doi: 10.1136/thx.2009.134353. [PMID: 20671305]
  • Paolo Solla, Antonino Cannas, Francesco Marrosu, Maria Giovanna Marrosu. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatric disease and treatment. 2010 Sep; 6(?):483-90. doi: 10.2147/ndt.s5190. [PMID: 20856911]
  • Jessica A Knight, Carol Smith, Nicole Toohey, Michael T Klein, Milt Teitler. Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Molecular pharmacology. 2009 Feb; 75(2):374-80. doi: 10.1124/mol.108.052084. [PMID: 18996971]
  • A Vinuela, P J Hallett, C Reske-Nielsen, M Patterson, T D Sotnikova, M G Caron, R R Gainetdinov, O Isacson. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain : a journal of neurology. 2008 Dec; 131(Pt 12):3361-79. doi: 10.1093/brain/awn192. [PMID: 18988638]
  • Oyvind Hauso, Björn I Gustafsson, Ivar S Nordrum, Helge L Waldum. The effect of terguride in carbon tetrachloride-induced liver fibrosis in rat. Experimental biology and medicine (Maywood, N.J.). 2008 Nov; 233(11):1385-8. doi: 10.3181/0804-rm-137. [PMID: 18703754]
  • Angelo Antonini, Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, Marco Onofrj, Mario Zappia, Aldo Quattrone. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. Neuropsychiatric disease and treatment. 2008 Feb; 4(1):1-9. doi: 10.2147/ndt.s2404. [PMID: 18728767]
  • Joseph Jankovic, Mark Stacy. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS drugs. 2007; 21(8):677-92. doi: 10.2165/00023210-200721080-00005. [PMID: 17630819]
  • Dag Nyholm. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clinical pharmacokinetics. 2006; 45(2):109-36. doi: 10.2165/00003088-200645020-00001. [PMID: 16485914]
  • Lorenzo Priano, Maria Rosa Gasco, Alessandro Mauro. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs & aging. 2006; 23(5):357-75. doi: 10.2165/00002512-200623050-00001. [PMID: 16823990]
  • Heike Benes. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep medicine. 2006 Jan; 7(1):31-5. doi: 10.1016/j.sleep.2005.05.007. [PMID: 16194624]
  • Yasuhiko Yamada, Naoko Irizuki, Risa Takayanagi, Koujirou Yamamoto, Yasufumi Sawada, Tatsuji Iga. [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2003 Apr; 123(4):255-60. doi: 10.1248/yakushi.123.255. [PMID: 12704865]
  • Shigeatsu Hashimoto, Jun-ichi Yatabe, Sanae Midorikawa, Hironobu Sanada, Tsuyoshi Watanabe. Inhibition of growth hormone excess reduces insulin resistance and ovarian dysfunction in a lean case of polycystic ovary syndrome with a growth-hormone-producing pituitary adenoma. Hormone research. 2003; 59(3):149-55. doi: 10.1159/000069064. [PMID: 12637795]
  • Yoshiyasu Iwai, Kazuhiro Yamanaka, Tomoya Ishiguro, Toshie Morikawa, Yasuhiro Matsuzaka, Masaki Komiyama, Toshihiro Yasui. [Results of treatment for male prolactinomas]. No shinkei geka. Neurological surgery. 2002 Dec; 30(12):1285-92. doi: NULL. [PMID: 12491580]
  • S Zorad, V Golda, M Fickova, L Macho, L Pinterova, J Jurcovicova. Terguride treatment attenuated prolactin release and enhanced insulin receptor affinity and GLUT 4 content in obese spontaneously hypertensive female, but not male rats. Annals of the New York Academy of Sciences. 2002 Jun; 967(?):490-9. doi: 10.1111/j.1749-6632.2002.tb04307.x. [PMID: 12079879]
  • X G Xia, N Schmidt, P Teismann, B Ferger, J B Schulz. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. Journal of neurochemistry. 2001 Oct; 79(1):63-70. doi: 10.1046/j.1471-4159.2001.00525.x. [PMID: 11595758]
  • V Golda, M Ficková, L Pinterova, J Jurcovicová, L Macho, S Zórad. Terguride attenuates prolactin levels and ameliorates insulin sensitivity and insulin binding in obese spontaneously hypertensive rats. Physiological research. 2001; 50(2):175-82. doi: NULL. [PMID: 11522045]
  • S Asano, K Ueki, I Suzuki, T Kirino. Clinical features and medical treatment of male prolactinomas. Acta neurochirurgica. 2001; 143(5):465-70. doi: 10.1007/s007010170075. [PMID: 11482696]
  • M Krsek, V Hána, J Marek, V Justová, Z Lacinová. [Combined therapy of acromegaly with a combination of lanreotide and terguride]. Casopis lekaru ceskych. 2000 Nov; 139(22):690-2. doi: NULL. [PMID: 11191748]
  • P De Vries, P A De Visser, J P Heiligers, C M Villalón, P R Saxena. Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. Naunyn-Schmiedeberg's archives of pharmacology. 1999 Apr; 359(4):331-8. doi: 10.1007/pl00005359. [PMID: 10344532]
  • R M Moresco, C Loc'h, M Ottaviani, B Guibert, V Leviel, M Maziere, F Fazio, B Maziere. Effects of dopamine on the in vivo binding of dopamine D2 receptor radioligands in rat striatum. Nuclear medicine and biology. 1999 Jan; 26(1):91-8. doi: 10.1016/s0969-8051(98)00048-1. [PMID: 10096507]
  • V Golda, J Hilgertová. Effect of long lasting terguride treatment on mutual relationship between glycide and lipid parameters in SHR/N-cp Koletsky rats. Acta medica (Hradec Kralove). 1998; 41(1):13-7. doi: . [PMID: 9588067]
  • V Golda. Ambivalent effect of long lasting terguride treatment on genetically based glycide and lipid metabolism abnormalities in SHR/N-cp Koletsky rats. Acta medica (Hradec Kralove). 1998; 41(2):81-5. doi: . [PMID: 9729641]
  • V Golda, J Jurcovicová. Hyperprolactinemia in obese as well as in lean females of Koletsky rats: effect of long lasting terguride treatment. Acta medica (Hradec Kralove). 1998; 41(4):159-62. doi: 10.14712/18059694.2019.182. [PMID: 9951046]
  • K Yonezawa, N Tamaki, T Kokunai. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat. Neurologia medico-chirurgica. 1997 Dec; 37(12):901-6. doi: 10.2176/nmc.37.901. [PMID: 9465588]
  • F G Boess, F J Monsma, V Meyer, C Zwingelstein, A J Sleight. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor. Molecular pharmacology. 1997 Sep; 52(3):515-23. doi: 10.1124/mol.52.3.515. [PMID: 9284367]
  • V Golda, J Hilgertová. Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats. Physiological research. 1997; 46(6):439-42. doi: NULL. [PMID: 9730050]
  • G Micieli, E Martignoni, A Cavallini, C Pacchetti, F Rossi, R Horowski, G Nappi. Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects. Functional neurology. 1996 Nov; 11(6):317-25. doi: NULL. [PMID: 9074912]
  • V Golda, J Hilgertová. Multiple regression analysis of parameters of lipid and glycide metabolism in obese and lean genetically hypertensive Koletsky rats under long lasting terguride treatment. Acta medica (Hradec Kralove). 1996; 39(4):141-7. doi: . [PMID: 9270120]
  • M Cordes, J Hierholzer, L Schelosky, A Schrag, W S Richter, H Eichstädt, P E Schulze, W Poewe, R Felix. Iodine-123-iodo-lisuride SPECT in Parkinson's disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1996 Jan; 37(1):22-5. doi: NULL. [PMID: 8543995]
  • J Sochor, J Klimes, M Srumová. High-performance liquid chromatographic determination of terguride in solid dosage forms and plasma. Journal of chromatography. B, Biomedical applications. 1995 Jan; 663(2):309-13. doi: 10.1016/0378-4347(94)00438-b. [PMID: 7735478]
  • W Krause, F Reissmann, G Kühne, C Schöbel. Circadian plasma level profile of lisuride in rats and mice after continuous administration via the diet. Arzneimittel-Forschung. 1995 Jan; 45(1):6-10. doi: NULL. [PMID: 7893271]
  • G Pezzoli, M Canesi, A Pesenti, C B Mariani. Pergolide mesylate in Parkinson's disease treatment. Journal of neural transmission. Supplementum. 1995; 45(?):203-12. doi: NULL. [PMID: 8748627]
  • V Golda, L Cvak. Terguride but not bromocriptine alleviated glucose tolerance abnormalities and hyperlipidaemia in obese and lean genetically hypertensive Koletsky rats. Physiological research. 1994; 43(5):299-305. doi: NULL. [PMID: 7711008]
  • F Stocchi, P N Patsalos, A Berardelli, L Barbato, A Bonamartini, M Manfredi, S Ruggieri. Clinical implications of sustained dopaminergic stimulation. Clinical neuropharmacology. 1994; 17 Suppl 2(?):S7-13. doi: NULL. [PMID: 9358190]
  • C Morán, G Tena, M E Fonseca, R Ochoa, J A Bermúdez, A Zárate. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy. Archives of medical research. 1994; 25(1):1-3. doi: NULL. [PMID: 8019107]
  • B G Wolthers, W D Verhagen Kamerbeek, C M van Beusekom, F Elshof, A W de Ruyter Buitenhuis, E P Brunt, J P Lakke. Quantitative determination of the dopamine agonist lisuride in plasma using high-performance liquid chromatography with fluorescence detection. Journal of chromatography. 1993 Dec; 622(1):33-8. doi: 10.1016/0378-4347(93)80246-z. [PMID: 8120110]
  • T Mizokawa, T Akai, Y Nakada, M Yamaguchi, H Nakagawa, S Hasan, K J Rettig, H Wachtel. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine. Japanese journal of pharmacology. 1993 Nov; 63(3):269-78. doi: 10.1254/jjp.63.269. [PMID: 7906316]
  • Y Shen, F J Monsma, M A Metcalf, P A Jose, M W Hamblin, D R Sibley. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. The Journal of biological chemistry. 1993 Aug; 268(24):18200-4. doi: . [PMID: 8394362]
  • G Sliutz, P Speiser, A M Schultz, J Spona, R Zeillinger. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1993 May; 25(5):253-5. doi: 10.1055/s-2007-1002090. [PMID: 8330858]
  • R G Robles, E Villa, A Andres, J Martinez, L M Ruilope, J M Sancho. Natriuretic effects of dopamine agonist drugs in models of reduced renal mass. Journal of cardiovascular pharmacology. 1993; 22 Suppl 2(?):S88-92. doi: 10.1097/00005344-199322002-00029. [PMID: 7508041]
  • J M Rabey, Y Vered, H Shabtai, E Graff, A D Korczyn. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. Journal of neurology, neurosurgery, and psychiatry. 1992 Aug; 55(8):725-7. doi: 10.1136/jnnp.55.8.725. [PMID: 1527547]
  • J Delforge, C Loc'h, P Hantraye, O Stulzaft, M Khalili-Varasteh, M Mazière, A Syrota, B Mazière. Kinetic analysis of central [76Br]bromolisuride binding to dopamine D2 receptors studied by PET. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1991 Nov; 11(6):914-25. doi: 10.1038/jcbfm.1991.156. [PMID: 1834685]
  • T Svoboda, A Luger, E Knosp, G Geyer. [Treatment of prolactinoma with a new dopamine agonist]. Deutsche medizinische Wochenschrift (1946). 1991 Aug; 116(33):1224-7. doi: 10.1055/s-2008-1063739. [PMID: 1678695]
  • J E Vázquez Martinez, C M Vázquez Benitez. [Treatment of the hyperprolactinemic states with lisuride in a simple open study]. Ginecologia y obstetricia de Mexico. 1991 Jun; 59(?):202-5. doi: NULL. [PMID: 1937125]
  • W Krause, G Kühne, W Seifert. Pharmacokinetics of 3H-terguride in elderly volunteers. Arzneimittel-Forschung. 1991 Apr; 41(4):373-7. doi: NULL. [PMID: 1859510]
  • C Nappi, F Petraglia, B M de Chiara, A D Genazzani, R Montemagno, A R Genazzani, U Montemagno. The effect of various drugs with neuroendocrine activity and transdermal estradiol on plasma gonadotropin concentrations after ovariectomy in reproductive-aged women. Acta obstetricia et gynecologica Scandinavica. 1991; 70(6):435-9. doi: 10.3109/00016349109007156. [PMID: 1763606]
  • W Krause, T Mager, G Kühne, T Duka, B Voet. The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection. European journal of clinical pharmacology. 1991; 40(4):399-403. doi: 10.1007/bf00265851. [PMID: 2050175]
  • B Sczesni, J Schröder, H Becker, H Przuntek. [Neuroleptic malignant syndrome]. Wiener klinische Wochenschrift. 1991; 103(1):1-7. doi: NULL. [PMID: 1673041]
  • A Rojanasakul, R Sirimongkolkasem, L O Chailurkit. The efficacy of lisuride in the treatment of hyperprolactinemic amenorrhea. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 1990 Feb; 73 Suppl 1(?):42-6. doi: NULL. [PMID: 2351912]
  • W Krause, H Träger, G Kühne, N Sauerbrey, K J Gräf, R Dorow. Pharmacokinetics and endocrine effects of terguride in healthy subjects. European journal of clinical pharmacology. 1990; 38(6):609-15. doi: 10.1007/bf00278591. [PMID: 2373136]
  • G Micieli, E Martignoni, G Bono, A Cavallini, F Rossi, R Horowski, G Nappi. A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain. Clinical neuropharmacology. 1989 Oct; 12(5):404-15. doi: 10.1097/00002826-198910000-00005. [PMID: 2692810]
  • M Carlsson, E Eriksson. The enhanced responsiveness of hypophyseal DA receptors in female rats induced by repeated reserpine treatment is not due to decreased oestrogen secretion. Pharmacology & toxicology. 1989 Sep; 65(3):236-8. doi: 10.1111/j.1600-0773.1989.tb01163.x. [PMID: 2813297]
  • M Berezin, U Elchalal, D Olchovsky. [Treatment of hyperprolactinemia and acromegaly with lisuride]. Harefuah. 1989 Jun; 116(12):634-7. doi: NULL. [PMID: 2792946]
  • R Lapka, P Krejci, J Lidický, M Frühaufová, K Rezábek. Pharmacokinetics and pharmacodynamics of terguride following intramuscular administration in cows and goats. Acta physiologica Polonica. 1989 Jan; 40(1):139-44. doi: NULL. [PMID: 2603744]
  • W Krause, M Hümpel. Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. European journal of drug metabolism and pharmacokinetics. 1988 Jul; 13(3):185-94. doi: 10.1007/bf03189938. [PMID: 3240764]
  • R Placzek, F Krassnigg, W B Schill. Effect of ace-inhibitors, calmodulin antagonists, acetylcholine receptor blocking, and alpha receptor blocking agents on motility of human sperm. Archives of andrology. 1988; 21(1):1-10. doi: 10.3109/01485018808986726. [PMID: 2903725]
  • W Krause, B Nieuweboer, S Ruggieri, F Stocchi, I Suchy. Pharmacokinetics of lisuride after subcutaneous infusion. Journal of neural transmission. Supplementum. 1988; 27(?):71-4. doi: 10.1007/978-3-7091-8954-2_8. [PMID: 3165439]
  • H G Bohnet, K Kato, H De Moll. Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women. Obstetrics and gynecology. 1988 Jan; 71(1):53-5. doi: NULL. [PMID: 3336541]
  • R Garcia-Robles, L M Ruilope, J Tovar, P de Pablos, J Parada, A Hurtado, B Miranda, G Fernandez Vazquez, J L Rodicio, J Sancho. Dopaminergic modulation of aldosterone secretion in the normal menstrual cycle. Journal of clinical hypertension. 1987 Dec; 3(4):470-8. doi: NULL. [PMID: 3134515]
  • M Carlsson, A Carlsson, E Eriksson. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. European journal of pharmacology. 1987 Oct; 142(1):39-43. doi: 10.1016/0014-2999(87)90651-0. [PMID: 3691635]
  • U Hamester, W Saeger, D K Lüdecke. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists. Histology and histopathology. 1987 Apr; 2(2):135-42. doi: NULL. [PMID: 2980713]
  • M Hilderbrand, M Hümpel, W Krause, U Täuber. Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog. European journal of drug metabolism and pharmacokinetics. 1987 Jan; 12(1):31-40. doi: 10.1007/bf03189859. [PMID: 3609071]
  • P Critchley, D Parkes. Transdihydrolisuride in parkinsonism. Clinical neuropharmacology. 1987; 10(1):57-64. doi: 10.1097/00002826-198702000-00005. [PMID: 3815388]
  • T Brücke, W Danielczyk, M Simányi, E Sofic, P Riederer. Terguride: partial dopamine agonist in the treatment of Parkinson's disease. Advances in neurology. 1987; 45(?):573-6. doi: NULL. [PMID: 3825735]
  • H Stracke, W Heinlein, R Horowski, H Schatz. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Arzneimittel-Forschung. 1986 Dec; 36(12):1834-6. doi: NULL. [PMID: 3566845]
  • D Dallabonzana, A Liuzzi, G Oppizzi, R Cozzi, G Verde, P Chiodini, E Rainer, R Dorow, R Horowski. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. The Journal of clinical endocrinology and metabolism. 1986 Oct; 63(4):1002-7. doi: 10.1210/jcem-63-4-1002. [PMID: 3745401]
  • R García-Robles, L Ruilope, J Tovar, L F de Villa, B Miranda, C Prieto, J Parada, J Sancho, J L Rodicio. Dopamine control of aldosterone secretion in end-stage renal failure. Revista espanola de fisiologia. 1986 Jun; 42(2):257-63. doi: NULL. [PMID: 3092288]
  • R Lapka, J Marek, V Rejholec, Z Franc. Pharmacokinetics of oral terguride in patients with a prolactinoma. European journal of clinical pharmacology. 1986; 30(3):363-5. doi: 10.1007/bf00541546. [PMID: 3732377]
  • W Krause, N Sauerbrey, K J Gräf. Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. European journal of clinical pharmacology. 1986; 31(2):165-8. doi: 10.1007/bf00606653. [PMID: 3803415]
  • G Brabant, I Brennecke, H Herrmann, H Friedrich, T O Wagner, A von zur Mühlen, R D Hesch. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy]. Deutsche medizinische Wochenschrift (1946). 1985 Oct; 110(41):1564-7. doi: 10.1055/s-2008-1069047. [PMID: 4042883]
  • K Koizumi, T Aono, K Kurachi. The effect of lisuride hydrogen maleate on anterior pituitary hormones, oestradiol and cortisol in normal and hyperprolactinaemic women. European journal of obstetrics, gynecology, and reproductive biology. 1985 Jul; 20(1):19-26. doi: 10.1016/0028-2243(85)90079-6. [PMID: 3928413]
  • K Okada, T Yamauchi, K Oishi, T Hashimura, J Kawamura, O Yoshida. [Evaluation of the clinical effect of lisuride hydrogen maleate (SH-1072) on benign prostatic hypertrophy: on the clinical results and mechanism of action]. Hinyokika kiyo. Acta urologica Japonica. 1985 May; 31(5):885-93. doi: NULL. [PMID: 2413748]
  • D Dallabonzana, A Liuzzi, G Oppizzi, G Verde, P G Chiodini, R Dorow, R Horowski. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly. Journal of endocrinological investigation. 1985 Apr; 8(2):147-51. doi: 10.1007/bf03350671. [PMID: 4031381]
  • L Ruilope, R Garcia-Robles, C Paya, L F de Villa, B Miranda, J M Morales, J Parada, J Sancho, J L Rodicio. Influence of lisuride, a dopaminergic agonist, on the sexual function of male patients with chronic renal failure. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1985 Mar; 5(3):182-5. doi: 10.1016/s0272-6386(85)80048-2. [PMID: 3919573]
  • M Boscaro, G Merola, E Serafini, F Mantero. Effect of short and long-term administration of lisuride in Cushing's disease. Journal of endocrinological investigation. 1985 Feb; 8(1):13-7. doi: 10.1007/bf03350627. [PMID: 2985685]
  • M König, G Aumüller, E Völck-Badouin, H Matschinger. Fine structure and protein biosynthesis of the rat seminal vesicles under experimental conditions. Andrologia. 1985 Jan; 17(1):54-63. doi: 10.1111/j.1439-0272.1985.tb00959.x. [PMID: 3994002]
  • M Da Prada, H H Keller, L Pieri, R Kettler, W E Haefely. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia. 1984 Nov; 40(11):1165-72. doi: 10.1007/bf01946641. [PMID: 6437857]
  • M Hümpel, W Krause, G A Hoyer, H Wendt, G Pommerenke. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. European journal of drug metabolism and pharmacokinetics. 1984 Oct; 9(4):347-57. doi: 10.1007/bf03189685. [PMID: 6532807]
  • J Marek, J Kopecká. Urinary excretion of free catecholamines in long-term treatment with dopaminergic agonists. Experimental and clinical endocrinology. 1984 Oct; 84(2):183-90. doi: 10.1055/s-0029-1210385. [PMID: 6151906]
  • R Lapka, S Smolík, Z Franc. Radioreceptor assay for ergot derivatives, transdihydrolisuride and lisuride, in biological fluids. Journal of pharmacological methods. 1984 Jul; 11(4):263-70. doi: 10.1016/0160-5402(84)90044-5. [PMID: 6738081]
  • G Oppizzi, A Liuzzi, P Chiodini, D Dallabonzana, B Spelta, F Silvestrini, G Borghi, C Tonon. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. The Journal of clinical endocrinology and metabolism. 1984 Jun; 58(6):988-92. doi: 10.1210/jcem-58-6-988. [PMID: 6725515]
  • R S Burns, G Gopinathan, M Hümpel, R Dorow, D B Calne. Disposition of oral lisuride in Parkinson's disease. Clinical pharmacology and therapeutics. 1984 Apr; 35(4):548-56. doi: 10.1038/clpt.1984.76. [PMID: 6705456]
  • S Götze, Y Nishino, F Neumann. Anti-oestrogenic effects of tamoxifen on mammary gland and hypophysis in female rats. Acta endocrinologica. 1984 Mar; 105(3):360-70. doi: 10.1530/acta.0.1050360. [PMID: 6702402]
  • A I Esquifino, J A Ramos, J A Tresguerres. Possible role of dopamine in changes in LH and prolactin concentrations after experimentally induced hyperprolactinaemia in rats. The Journal of endocrinology. 1984 Feb; 100(2):141-8. doi: 10.1677/joe.0.1000141. [PMID: 6363589]
  • W Krause, R Dorow, B Nieuweboer, S H Hasan. Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. European journal of clinical pharmacology. 1984; 27(3):335-9. doi: 10.1007/bf00542171. [PMID: 6510462]
  • J Marek, K Rezábek, J Srámková. [Drug therapy of hyperprolactinemia, acromegaly and Cushing syndrome]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete. 1983 Nov; 38(22):246-8. doi: . [PMID: 6666180]
  • V Locatelli, F Petraglia, A Penalva, A E Panerai. Effect of dopaminergic drugs on hypothalamic and pituitary immunoreactive beta-endorphin concentrations in the rat. Life sciences. 1983 Oct; 33(17):1711-7. doi: 10.1016/0024-3205(83)90728-2. [PMID: 6314082]
  • A Giarola. [Indications for hormone therapy of female secretory sterility]. Minerva medica. 1983 May; 74(19):1097-126. doi: . [PMID: 6341886]
  • V Schreiber, T Pribyl, J Jahodová. Inhibition of the oestradiol-induced increase in adenohypophyseal weight and in hypothalamic and serum polyphenol oxidase activity by dopaminergic agonists. Physiologia Bohemoslovaca. 1983; 32(2):117-20. doi: . [PMID: 6408657]
  • J A Tresguerres, A I Esquifino. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model]. Acta physiologica latino americana. 1983; 33(3):257-74. doi: NULL. [PMID: 6424409]
  • K Hara, Y Ikoma, H Nakao, K Ezumi, N Oshino, C Shiota, S Sasagawa. [Central dopaminergic function in stroke-prone spontaneously hypertensive rats (SHRSP): II. Effects of chronic treatment with lisuride on the impaired swimming ability]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1982 Nov; 80(5):385-94. doi: NULL. [PMID: 7166283]
  • K J Gräf, M Schmidt-Gollwitzer, R Horowski, R Dorow. Effect of metoclopramide and lisuride on hypophyseal and gonadal function in men. Clinical endocrinology. 1982 Sep; 17(3):243-51. doi: 10.1111/j.1365-2265.1982.tb01586.x. [PMID: 6819898]
  • G Scotti, G Scialfa, S Pieralli, P G Chiodini, B Spelta, D Dallabonzana. Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment. Neuroradiology. 1982; 23(3):123-6. doi: 10.1007/bf00347554. [PMID: 7088281]
  • A Martinez-Campos, P Giovannini, E Parati, A Novelli, T Caraceni, E E Müller. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry. 1981 Dec; 44(12):1116-23. doi: 10.1136/jnnp.44.12.1116. [PMID: 7334406]
  • J Marek, J Srámková, M Schüllerová, J Stĕpán, O Schreiberová. Long-term treatment of acromegaly with lisuride: differences of effect on growth hormone and somatomedin. Endokrinologie. 1981 Dec; 78(2-3):175-85. doi: NULL. [PMID: 7037372]